🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06455020
Starting soon Not applicable

Catheter Ablation of Haemodynamically Not-tolerated Electrical Storm in Structural Heart Disease

NCT06455020 · tracked via the Priya Life Science China tracker
Sponsor
Beijing Anzhen Hospital
Phase
Not applicable
Started
2024-07-01
Last updated
2024-06-12

Condition(s) studied

Ventricular Tachycardia

Investigational drug(s) / intervention(s)

Catheter ablationStepped-care strategies

Catheter ablation: Emergency catheter ablation is defined as ablation performed within 48 hours of hospital admission

Stepped-care strategies: Patients randomized to the stepped-care strategy arm will receive treatment through a systematic, stepwise protocol beginning with anti-arrhythmic drugs, followed by sedation and anesthesia, and progressing to haemodynamic mechanical support devices if earlier treatments prove ineffective. Catheter ablation will be reserved as the final rescue intervention.

Study summary

This is a multi-center, parallel-group, randomized, open-label trial evaluating the clinical outcome and efficacy of emergency catheter ablation versus conventional stepped-care strategies in patients with haemodynamically not-tolerated ventricular tachycardia (VT).

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: 1. Patients aged 18 to 80 years; 2. Having structural heart disease, including ischemic cardiomyopathy and nonischemic cardiomyopathy; 3. Haemodynamically not-tolerated, defined as persistent hypotension (systolic blood pressure \<90 mmHg and mean arterial pressure 30 mmHg lower than baseline or \<70 mmHg, with associated signs of end-organ hypoperfusion); 4. Electrical storm, defined as \>3 VT episodes within 24 hours. Exclusion Criteria: 1. Reversible causes of ventricular tachycardia or cardiomyopathy; 2. Ventricular thrombosis diagnosed by echocardiography and/or cardiac magnetic resonance; 3. Acute ST-segment-elevation myocardial infarction within 60 days; 4. Cardiac surgery within 60 days; 5. Unstable angina; 6. Pregnancy.

Primary outcome measure(s)

Trial sites (4)

FacilityCityRegionStatus
Beijing Anzhen Hospital, Capital Medical University Beijing China
Second Xiangya Hospital, Central South University Changsha China
The Affiliated YanAn Hospital of KunMing Medical University Kunming China
The First Affiliated Hospital of Nanjing Medical University Nanjing China

More Beijing Anzhen Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06455020 on ClinicalTrials.gov ↗ ← All trials in China